APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasma Products and Derivatives

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Plasma Products and Derivatives Market Outlook and Growth Opportunities 2026

2 January 2026209 pages

Choose your research edition.

Industry ResearchPlasma Products and Derivatives Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma Products and Derivatives Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Plasma Products and Derivatives Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma Products and Derivatives Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma Products and Derivatives Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Plasma Products and Derivatives market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Plasma Products and Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Plasma Products and Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Plasma Products and Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Plasma Products and Derivatives market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Plasma Products and Derivatives market include Takeda, RAAS, Shuanglin Bio, Hualan Bio, Tiantan Bio, Yuanda Shuyang, Weiguang Bio, Octapharma and Nanyue Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Plasma Products and Derivatives market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Plasma Products and Derivatives and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Plasma Products and Derivatives revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Plasma Products and Derivatives market.

Plasma Products and Derivatives Segment by Company

Takeda

RAAS

Shuanglin Bio

Hualan Bio

Tiantan Bio

Yuanda Shuyang

Weiguang Bio

Octapharma

Nanyue Bio

LFB Group

KM Biologics

Kedrion

Grifols

CSL

CBPO

BPL

Boya Bio

Biotest

Plasma Products and Derivatives Segment by Type

Albumin

Immune Globulin

Coagulation Factor

Others

Plasma Products and Derivatives Segment by Application

Hospital

Retail Pharmacy

Others

Plasma Products and Derivatives Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Plasma Products and Derivatives status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Plasma Products and Derivatives key companies, revenue, market share, and recent developments.

3. To split the Plasma Products and Derivatives breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Plasma Products and Derivatives market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Plasma Products and Derivatives significant trends, drivers, influence factors in global and regions.

6. To analyze Plasma Products and Derivatives competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Products and Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma Products and Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Products and Derivatives.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Products and Derivatives industry.

Chapter 3: Detailed analysis of Plasma Products and Derivatives company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Plasma Products and Derivatives in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Plasma Products and Derivatives in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Plasma Products and Derivatives Industry Trends Table 2. Plasma Products and Derivatives Industry Drivers Table 3. Plasma Products and Derivatives Industry Opportunities and Challenges Table 4. Plasma Products and Derivatives Industry Restraints Table 5. Global Plasma Products and Derivatives Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Plasma Products and Derivatives Revenue Share by Company (2021-2026) Table 7. Global Plasma Products and Derivatives Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Plasma Products and Derivatives Key Company Manufacturing Base & Headquarters Table 9. Global Plasma Products and Derivatives Company, Product Type & Application Table 10. Global Plasma Products and Derivatives Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Plasma Products and Derivatives by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Albumin Table 15. Significant Companies of Immune Globulin Table 16. Significant Companies of Coagulation Factor Table 17. Significant Companies of Others Table 18. Global Plasma Products and Derivatives Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Plasma Products and Derivatives Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Plasma Products and Derivatives Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Plasma Products and Derivatives Sales Value Share by Type (2021-2026) Table 22. Global Plasma Products and Derivatives Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Others Table 26. Global Plasma Products and Derivatives Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Plasma Products and Derivatives Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Plasma Products and Derivatives Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Plasma Products and Derivatives Sales Value Share by Application (2021-2026) Table 30. Global Plasma Products and Derivatives Sales Value Share by Application (2027-2032) Table 31. Global Plasma Products and Derivatives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Plasma Products and Derivatives Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Plasma Products and Derivatives Sales Value Share by Region (2021-2026) Table 34. Global Plasma Products and Derivatives Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Plasma Products and Derivatives Sales Value Share by Region (2027-2032) Table 36. Global Plasma Products and Derivatives Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Plasma Products and Derivatives Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Plasma Products and Derivatives Sales Value Market Share by Country (2021-2026) Table 39. Global Plasma Products and Derivatives Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Plasma Products and Derivatives Sales Value Market Share by Country (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Plasma Products and Derivatives Product Portfolio Table 45. Takeda Recent Development Table 46. RAAS Company Information Table 47. RAAS Business Overview Table 48. RAAS Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. RAAS Plasma Products and Derivatives Product Portfolio Table 50. RAAS Recent Development Table 51. Shuanglin Bio Company Information Table 52. Shuanglin Bio Business Overview Table 53. Shuanglin Bio Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Shuanglin Bio Plasma Products and Derivatives Product Portfolio Table 55. Shuanglin Bio Recent Development Table 56. Hualan Bio Company Information Table 57. Hualan Bio Business Overview Table 58. Hualan Bio Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Hualan Bio Plasma Products and Derivatives Product Portfolio Table 60. Hualan Bio Recent Development Table 61. Tiantan Bio Company Information Table 62. Tiantan Bio Business Overview Table 63. Tiantan Bio Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Tiantan Bio Plasma Products and Derivatives Product Portfolio Table 65. Tiantan Bio Recent Development Table 66. Yuanda Shuyang Company Information Table 67. Yuanda Shuyang Business Overview Table 68. Yuanda Shuyang Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Yuanda Shuyang Plasma Products and Derivatives Product Portfolio Table 70. Yuanda Shuyang Recent Development Table 71. Weiguang Bio Company Information Table 72. Weiguang Bio Business Overview Table 73. Weiguang Bio Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Weiguang Bio Plasma Products and Derivatives Product Portfolio Table 75. Weiguang Bio Recent Development Table 76. Octapharma Company Information Table 77. Octapharma Business Overview Table 78. Octapharma Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Octapharma Plasma Products and Derivatives Product Portfolio Table 80. Octapharma Recent Development Table 81. Nanyue Bio Company Information Table 82. Nanyue Bio Business Overview Table 83. Nanyue Bio Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Nanyue Bio Plasma Products and Derivatives Product Portfolio Table 85. Nanyue Bio Recent Development Table 86. LFB Group Company Information Table 87. LFB Group Business Overview Table 88. LFB Group Plasma Products and Derivatives Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. LFB Group Plasma Products and Derivatives Product Portfolio Table 90. LFB Group Recent Development Table 91. KM Biologics Company Information Table 92. KM Biologics Business Overview Table 93. KM Biologics Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. KM Biologics Plasma Products and Derivatives Product Portfolio Table 95. KM Biologics Recent Development Table 96. Kedrion Company Information Table 97. Kedrion Business Overview Table 98. Kedrion Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Kedrion Plasma Products and Derivatives Product Portfolio Table 100. Kedrion Recent Development Table 101. Grifols Company Information Table 102. Grifols Business Overview Table 103. Grifols Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Grifols Plasma Products and Derivatives Product Portfolio Table 105. Grifols Recent Development Table 106. CSL Company Information Table 107. CSL Business Overview Table 108. CSL Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. CSL Plasma Products and Derivatives Product Portfolio Table 110. CSL Recent Development Table 111. CBPO Company Information Table 112. CBPO Business Overview Table 113. CBPO Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. CBPO Plasma Products and Derivatives Product Portfolio Table 115. CBPO Recent Development Table 116. BPL Company Information Table 117. BPL Business Overview Table 118. BPL Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. BPL Plasma Products and Derivatives Product Portfolio Table 120. BPL Recent Development Table 121. Boya Bio Company Information Table 122. Boya Bio Business Overview Table 123. Boya Bio Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Boya Bio Plasma Products and Derivatives Product Portfolio Table 125. Boya Bio Recent Development Table 126. Biotest Company Information Table 127. Biotest Business Overview Table 128. Biotest Plasma Products and Derivatives Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Biotest Plasma Products and Derivatives Product Portfolio Table 130. Biotest Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Plasma Products and Derivatives Product Image Figure 2. Global Plasma Products and Derivatives Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma Products and Derivatives Market Size (2021-2032) & (US$ Million) Figure 4. Global Plasma Products and Derivatives Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Albumin Image Figure 8. Immune Globulin Image Figure 9. Coagulation Factor Image Figure 10. Others Image Figure 11. Global Plasma Products and Derivatives Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Plasma Products and Derivatives Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Plasma Products and Derivatives Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Pharmacy Image Figure 16. Others Image Figure 17. Global Plasma Products and Derivatives Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Plasma Products and Derivatives Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Plasma Products and Derivatives Sales Value Share by Application (2021-2032) Figure 20. Global Plasma Products and Derivatives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Plasma Products and Derivatives Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Plasma Products and Derivatives Sales Value (2021-2032) & (US$ Million) Figure 23. North America Plasma Products and Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Plasma Products and Derivatives Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Plasma Products and Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Plasma Products and Derivatives Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Plasma Products and Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Plasma Products and Derivatives Sales Value (2021-2032) & (US$ Million) Figure 29. South America Plasma Products and Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Plasma Products and Derivatives Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Plasma Products and Derivatives Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Plasma Products and Derivatives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Immune Globulin
  • Coagulation Factor
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Takeda
  • RAAS
  • Shuanglin Bio
  • Hualan Bio
  • Tiantan Bio
  • Yuanda Shuyang
  • Weiguang Bio
  • Octapharma
  • Nanyue Bio
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • CBPO
  • BPL
  • Boya Bio
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Plasma Products and Derivatives Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Plasma Products and Derivatives Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Plasma Products and Derivatives Market Dynamics
  1. 2.1 Plasma Products and Derivatives Industry Trends
  2. 2.2 Plasma Products and Derivatives Industry Drivers
  3. 2.3 Plasma Products and Derivatives Industry Opportunities and Challenges
  4. 2.4 Plasma Products and Derivatives Industry Restraints
3 Plasma Products and Derivatives Market by Company
  1. 3.1 Global Plasma Products and Derivatives Company Revenue Ranking in 2025
  2. 3.2 Global Plasma Products and Derivatives Revenue by Company (2021-2026)
  3. 3.3 Global Plasma Products and Derivatives Company Ranking (2024-2026)
  4. 3.4 Global Plasma Products and Derivatives Company Manufacturing Base and Headquarters
  5. 3.5 Global Plasma Products and Derivatives Company Product Type and Application
  6. 3.6 Global Plasma Products and Derivatives Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Plasma Products and Derivatives Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Plasma Products and Derivatives Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Plasma Products and Derivatives Market by Type
  1. 4.1 Plasma Products and Derivatives Type Introduction
  2. 4.1.1 Albumin
  3. 4.1.2 Immune Globulin
  4. 4.1.3 Coagulation Factor
  5. 4.1.4 Others
  6. 4.2 Global Plasma Products and Derivatives Sales Value by Type
  7. 4.2.1 Global Plasma Products and Derivatives Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Plasma Products and Derivatives Sales Value by Type (2021-2032)
  9. 4.2.3 Global Plasma Products and Derivatives Sales Value Share by Type (2021-2032)
5 Plasma Products and Derivatives Market by Application
  1. 5.1 Plasma Products and Derivatives Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Plasma Products and Derivatives Sales Value by Application
  6. 5.2.1 Global Plasma Products and Derivatives Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Plasma Products and Derivatives Sales Value by Application (2021-2032)
  8. 5.2.3 Global Plasma Products and Derivatives Sales Value Share by Application (2021-2032)
6 Plasma Products and Derivatives Regional Value Analysis
  1. 6.1 Global Plasma Products and Derivatives Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Plasma Products and Derivatives Sales Value by Region (2021-2032)
  3. 6.2.1 Global Plasma Products and Derivatives Sales Value by Region: 2021-2026
  4. 6.2.2 Global Plasma Products and Derivatives Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Plasma Products and Derivatives Sales Value (2021-2032)
  7. 6.3.2 North America Plasma Products and Derivatives Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Plasma Products and Derivatives Sales Value (2021-2032)
  10. 6.4.2 Europe Plasma Products and Derivatives Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Plasma Products and Derivatives Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Plasma Products and Derivatives Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Plasma Products and Derivatives Sales Value (2021-2032)
  16. 6.6.2 South America Plasma Products and Derivatives Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Plasma Products and Derivatives Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Plasma Products and Derivatives Sales Value Share by Country, 2025 VS 2032
7 Plasma Products and Derivatives Country-level Value Analysis
  1. 7.1 Global Plasma Products and Derivatives Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Plasma Products and Derivatives Sales Value by Country (2021-2032)
  3. 7.2.1 Global Plasma Products and Derivatives Sales Value by Country (2021-2026)
  4. 7.2.2 Global Plasma Products and Derivatives Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Plasma Products and Derivatives Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Plasma Products and Derivatives Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Plasma Products and Derivatives Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Plasma Products and Derivatives Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 RAAS
  8. 8.2.1 RAAS Company Information
  9. 8.2.2 RAAS Business Overview
  10. 8.2.3 RAAS Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  11. 8.2.4 RAAS Plasma Products and Derivatives Product Portfolio
  12. 8.2.5 RAAS Recent Developments
  13. 8.3 Shuanglin Bio
  14. 8.3.1 Shuanglin Bio Company Information
  15. 8.3.2 Shuanglin Bio Business Overview
  16. 8.3.3 Shuanglin Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shuanglin Bio Plasma Products and Derivatives Product Portfolio
  18. 8.3.5 Shuanglin Bio Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Plasma Products and Derivatives Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 Tiantan Bio
  26. 8.5.1 Tiantan Bio Company Information
  27. 8.5.2 Tiantan Bio Business Overview
  28. 8.5.3 Tiantan Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tiantan Bio Plasma Products and Derivatives Product Portfolio
  30. 8.5.5 Tiantan Bio Recent Developments
  31. 8.6 Yuanda Shuyang
  32. 8.6.1 Yuanda Shuyang Company Information
  33. 8.6.2 Yuanda Shuyang Business Overview
  34. 8.6.3 Yuanda Shuyang Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yuanda Shuyang Plasma Products and Derivatives Product Portfolio
  36. 8.6.5 Yuanda Shuyang Recent Developments
  37. 8.7 Weiguang Bio
  38. 8.7.1 Weiguang Bio Company Information
  39. 8.7.2 Weiguang Bio Business Overview
  40. 8.7.3 Weiguang Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Weiguang Bio Plasma Products and Derivatives Product Portfolio
  42. 8.7.5 Weiguang Bio Recent Developments
  43. 8.8 Octapharma
  44. 8.8.1 Octapharma Company Information
  45. 8.8.2 Octapharma Business Overview
  46. 8.8.3 Octapharma Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Octapharma Plasma Products and Derivatives Product Portfolio
  48. 8.8.5 Octapharma Recent Developments
  49. 8.9 Nanyue Bio
  50. 8.9.1 Nanyue Bio Company Information
  51. 8.9.2 Nanyue Bio Business Overview
  52. 8.9.3 Nanyue Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nanyue Bio Plasma Products and Derivatives Product Portfolio
  54. 8.9.5 Nanyue Bio Recent Developments
  55. 8.10 LFB Group
  56. 8.10.1 LFB Group Company Information
  57. 8.10.2 LFB Group Business Overview
  58. 8.10.3 LFB Group Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LFB Group Plasma Products and Derivatives Product Portfolio
  60. 8.10.5 LFB Group Recent Developments
  61. 8.11 KM Biologics
  62. 8.11.1 KM Biologics Company Information
  63. 8.11.2 KM Biologics Business Overview
  64. 8.11.3 KM Biologics Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  65. 8.11.4 KM Biologics Plasma Products and Derivatives Product Portfolio
  66. 8.11.5 KM Biologics Recent Developments
  67. 8.12 Kedrion
  68. 8.12.1 Kedrion Company Information
  69. 8.12.2 Kedrion Business Overview
  70. 8.12.3 Kedrion Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kedrion Plasma Products and Derivatives Product Portfolio
  72. 8.12.5 Kedrion Recent Developments
  73. 8.13 Grifols
  74. 8.13.1 Grifols Company Information
  75. 8.13.2 Grifols Business Overview
  76. 8.13.3 Grifols Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Grifols Plasma Products and Derivatives Product Portfolio
  78. 8.13.5 Grifols Recent Developments
  79. 8.14 CSL
  80. 8.14.1 CSL Company Information
  81. 8.14.2 CSL Business Overview
  82. 8.14.3 CSL Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CSL Plasma Products and Derivatives Product Portfolio
  84. 8.14.5 CSL Recent Developments
  85. 8.15 CBPO
  86. 8.15.1 CBPO Company Information
  87. 8.15.2 CBPO Business Overview
  88. 8.15.3 CBPO Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CBPO Plasma Products and Derivatives Product Portfolio
  90. 8.15.5 CBPO Recent Developments
  91. 8.16 BPL
  92. 8.16.1 BPL Company Information
  93. 8.16.2 BPL Business Overview
  94. 8.16.3 BPL Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BPL Plasma Products and Derivatives Product Portfolio
  96. 8.16.5 BPL Recent Developments
  97. 8.17 Boya Bio
  98. 8.17.1 Boya Bio Company Information
  99. 8.17.2 Boya Bio Business Overview
  100. 8.17.3 Boya Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Boya Bio Plasma Products and Derivatives Product Portfolio
  102. 8.17.5 Boya Bio Recent Developments
  103. 8.18 Biotest
  104. 8.18.1 Biotest Company Information
  105. 8.18.2 Biotest Business Overview
  106. 8.18.3 Biotest Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Biotest Plasma Products and Derivatives Product Portfolio
  108. 8.18.5 Biotest Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst